CD22
CD19
耐火材料(行星科学)
医学
淋巴细胞白血病
癌症研究
免疫学
靶向治疗
细胞疗法
白血病
清脆的
细胞
内科学
生物
癌症
抗原
基因
遗传学
天体生物学
作者
Yongxian Hu,Yali Zhou,Mingming Zhang,Wengang Ge,Yi Li,Li Yang,Guoqing Wei,Lu Han,Hao Wang,Shuhui Yu,Yi Chen,Yanbin Wang,Xiaohong He,Xingwang Zhang,Ming Gao,Jing‐Jing Yang,Xiuju Li,Jiangtao Ren,He Huang
标识
DOI:10.1158/1078-0432.ccr-20-3863
摘要
CRISPR/Cas9-engineered universal CD19/CD22 CAR-T cells exhibited a manageable safety profile and prominent antileukemia activity. Universal dual-targeted CAR-T cell therapy may offer an alternative therapy for patients with r/r ALL.
科研通智能强力驱动
Strongly Powered by AbleSci AI